【摘要】：目的:將多囊脂質(zhì)體(MVLs)用于包載齊墩果酸(OA),制備一種新型給藥系統(tǒng)齊墩果酸多囊脂質(zhì)體(OA-MVLs),克服OA的難溶性缺點,延長藥物的消除時間,并初步驗證OA-MVLs對正常人肝細胞L-02、人肝癌細胞HepG2和SMMC-7721細胞的抑制作用;擬考察利用最佳處方制備的OA-MVLs能否抑制肝癌細胞的遷移、侵襲,能否抑制腫瘤增長,降低毒副作用。方法:本研究采用已獲得的最優(yōu)處方制備OA-MVLs后,以肝癌細胞SMMC-7721和HepG2為細胞模型,分別給予不同劑量的OA-MVLs和OA,對細胞的活力、黏附、遷移和侵襲能力進行評價。隨后,通過大鼠體內(nèi)毒性實驗對OA-MVLs的毒副作用進行考察。最后,構(gòu)建H22荷瘤小鼠模型,對OA-MVLs的抗腫瘤活性進行檢測。結(jié)果:實驗結(jié)果表明,OA-MVLs能顯著降低體外肝癌細胞的活力、黏附、遷移和侵襲。此外,當濃度為160μmol/L時OA-MVLs對肝癌細胞有抑制作用,但是對正常肝細胞卻無影響。體內(nèi)毒性實驗表明,低、中劑量的OA-MVLs對實驗大鼠無毒副作用。OA-MVLs能抑制H22荷瘤小鼠腫瘤的生長并且延長其生存時間。結(jié)論:OA-MVLs能抑制體外肝癌細胞的生長、黏附、遷移和侵襲,具有抗腫瘤活性,能抑制腫瘤的生長,低、中劑量的OA-MVLs更適用于肝癌治療的劑量選擇。
[Abstract]:Objective: to prepare a new delivery system of oleanolic acid polythylated liposome (OA-MVLs) by using polythylated liposome (MVLs) for encapsulating oleanolic acid (OA),. The inhibitory effects of OA-MVLs on normal human hepatocytes L-02, HepG2 and SMMC-7721 cells were preliminarily tested, and whether the OA-MVLs prepared with the best prescription could inhibit the migration, invasion, tumor growth and toxicity of hepatoma cells. Methods: in this study, OA-MVLs was prepared with the best prescription. The cell models of SMMC-7721 and HepG2 were used to evaluate the viability, adhesion, migration and invasion of hepatoma cells by different doses of OA-MVLs and OA, respectively. Then, the toxicity and side effects of OA-MVLs were investigated in vivo. Finally, the anti-tumor activity of OA-MVLs was detected by constructing H 22 tumor-bearing mice model. Results: the results showed that OA-MVLs could significantly reduce the viability, adhesion, migration and invasion of hepatoma cells in vitro. In addition, at the concentration of 160 渭 mol/L, OA-MVLs inhibited hepatoma cells, but had no effect on normal hepatocytes. In vivo toxicity test showed that low and middle dose of OA-MVLs had no side effects on experimental rats. OA-MVLs could inhibit tumor growth and prolong survival time of H22 tumor-bearing mice. Conclusion: OA-MVLs can inhibit the growth, adhesion, migration and invasion of hepatoma cells in vitro. It has anti-tumor activity and can inhibit tumor growth. Low dose OA-MVLs is more suitable for the treatment of liver cancer.
【學位授予單位】：西南醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.7

【參考文獻】

相關(guān)期刊論文 前7條

1 馬培奇;;美FDA批準布比卡因脂質(zhì)體注射用懸浮液Exparel治療術(shù)后疼痛[J];上海醫(yī)藥;2012年15期

2 ;Study on Inhibitive Effect of Oleanolic Acid on Transplanted Hepatocarcinoma in Mice[J];Medicinal Plant;2011年03期

3 張淼;于葉玲;唐星;;阿糖胞苷多囊脂質(zhì)體的制備及體外釋放度考察[J];沈陽藥科大學學報;2009年01期

4 陶濤;;脂質(zhì)體遞藥系統(tǒng)的臨床研究進展[J];藥學服務(wù)與研究;2008年02期

5 ;TGF-β1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-β1-enhanced cell migration in SMMC-7721 cells[J];Cell Research;2003年05期

6 肖超菊,齊憲榮,艾尼瓦爾,魏樹禮;順鉑緩釋多囊脂質(zhì)體的制備和體外釋放性能研究[J];藥學學報;2003年02期

7 嚴文偉,肖超菊,齊憲榮,王文浩;水溶性藥物8-氯腺苷多囊脂質(zhì)體的制備[J];北京大學學報(醫(yī)學版);2002年04期

，

本文編號：2284061